Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5285912
Max Phase: Preclinical
Molecular Formula: C65H84N10O11
Molecular Weight: 1181.45
Associated Items:
ID: ALA5285912
Max Phase: Preclinical
Molecular Formula: C65H84N10O11
Molecular Weight: 1181.45
Associated Items:
Canonical SMILES: CC(C)C[C@@H](/C=C/[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=O)OCc1ccccc1)C(=O)Nc1ccc(COC(=O)N2CCCC2(C)c2nc3cccc(C(N)=O)c3[nH]2)cc1)C(C)C)NC(=O)OC(C)(C)C
Standard InChI: InChI=1S/C65H84N10O11/c1-41(2)37-48(69-62(82)86-64(5,6)7)32-29-46(38-43-19-11-9-12-20-43)59(80)74-35-17-26-52(74)57(78)72-53(42(3)4)58(79)70-51(25-16-34-67-61(81)84-39-44-21-13-10-14-22-44)56(77)68-47-30-27-45(28-31-47)40-85-63(83)75-36-18-33-65(75,8)60-71-50-24-15-23-49(55(66)76)54(50)73-60/h9-15,19-24,27-32,41-42,46,48,51-53H,16-18,25-26,33-40H2,1-8H3,(H2,66,76)(H,67,81)(H,68,77)(H,69,82)(H,70,79)(H,71,73)(H,72,78)/b32-29+/t46?,48-,51+,52+,53+,65?/m1/s1
Standard InChI Key: YRJCBTOROOHRDF-DFXILPKHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1181.45 | Molecular Weight (Monoisotopic): 1180.6321 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Borgini M, Wipf P.. (2023) Synthesis of Veliparib Prodrugs and Determination of Drug-Release-Dependent PARP-1 Inhibition., 14 (5): [PMID:37197461] [10.1021/acsmedchemlett.3c00065] |
Source(1):